Immutep (ASX:IMM): Is the Market Underestimating This Healthcare Growth Story?

Aditi Sarkar

02 September 2026 04:08 PM AEST

Immutep (ASX:IMM): Is the Market Underestimating This Healthcare Growth Story?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Immutep is developing immunotherapies based on the LAG-3 immune-control mechanism, led by its lead candidate eftilagimod alfa.
The company discontinued its TACTI-004 Phase III study after an interim futility analysis in first-line non-small cell lung cancer.
Immutep continues advancing other efti combination studies while maintaining a longer cash runway.
Future progress depends on clinical data, strategic decisions and potential Partnership opportunities.

Immutep Ltd (ASX:IMM) is a clinical-stage biotechnology company developing cancer immunotherapies based on the LAG-3 immune-control pathway. Its lead candidate, eftilagimod alfa (efti), is being evaluated in combination with established cancer treatments across several tumour types.

The company remains one of the more closely followed biotechnology names on the ASX due to the potential of LAG-3-based therapies in oncology. However, assessing Immutep’s outlook requires balancing the setback from a major clinical trial against the potential value of its broader development pipeline.

Latest Development

On 13 March 2026, Immutep Ltd (ASX:IMM) announced that its TACTI-004 Phase III trial in first-line non-small cell lung cancer would be discontinued after an Independent Data Monitoring Committee recommended stopping the study following a futility analysis.

The company stated that it was surprised and disappointed by the outcome given previous observations from other efti studies and planned to undertake a detailed review of the available data.

Following the decision, Immutep highlighted that removing TACTI-004-related costs would extend its expected cash runway beyond its previous guidance. In May 2026, the company also reported research findings linking efti-driven immune activation with improved overall survival outcomes in certain late-stage cancer patients.

Financial Performance

As a pre-revenue biotechnology company, Immutep Ltd’s (ASX:IMM) value is primarily linked to its clinical pipeline, research progress and available funding capacity rather than current earnings.

The discontinuation of TACTI-004 reduced a significant development expense but also removed one of the company’s most advanced clinical opportunities. This has changed the balance between risk and potential reward within the Investment case.

The company continued providing updates on its broader clinical activities through its FY26 quarterly reporting, with future progress dependent on remaining efti studies and the ability to advance those programs towards meaningful clinical milestones.

What Could Drive the Shares Next?

The next important developments for Immutep Ltd (ASX:IMM) will likely come from further analysis of the TACTI-004 outcome, strategic decisions regarding future research priorities and progress across remaining efti combination studies.

Positive clinical results from ongoing trials would represent a significant potential driver, particularly if they strengthen confidence in the LAG-3 approach.

Potential collaboration or partnership opportunities could also influence the company’s outlook by providing additional validation and supporting future development activities.

Key Risks

Immutep Ltd (ASX:IMM) faces the inherent risks associated with biotechnology development, where clinical trial outcomes can significantly influence the value of a company.

The TACTI-004 futility result highlighted the uncertainty involved in advancing new therapies, and further disappointing clinical outcomes could affect investor confidence.

The company also remains dependent on funding markets to support ongoing research programs, while competition in the immuno-oncology sector continues to increase.

Investor Outlook

Immutep Ltd (ASX:IMM) presents a more balanced investment narrative following the TACTI-004 setback. While the Phase III outcome represented a significant challenge, the company retains opportunities through its broader efti development program and an extended funding runway.

The company’s future direction will depend on upcoming clinical updates, strategic decisions and the ability to demonstrate meaningful progress across its remaining pipeline.

FAQs

Q: What does Immutep Ltd develop?

A:Immutep develops immunotherapies focused on the LAG-3 immune-control pathway, led by eftilagimod alfa.

Q: What happened with Immutep’s TACTI-004 trial?

A:The Phase III TACTI-004 trial was discontinued after an interim futility analysis.

Q: What is eftilagimod alfa (efti)?

A:Efti is Immutep’s lead immunotherapy candidate being studied in combination with other cancer treatments.

Q: What are the key growth drivers for Immutep?

A:Clinical trial progress, positive data outcomes and potential partnerships are key growth drivers.

Q: What are the main risks for Immutep?

A:Key risks include clinical trial uncertainty, funding requirements and competition within immuno-oncology.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.